<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949011</url>
  </required_header>
  <id_info>
    <org_study_id>1602T0832</org_study_id>
    <secondary_id>2016-002688-32</secondary_id>
    <nct_id>NCT02949011</nct_id>
  </id_info>
  <brief_title>Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications</brief_title>
  <acronym>CAPSTONE 2</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single, oral dose of
      baloxavir marboxil compared with placebo by measuring the time to improvement of influenza
      symptoms in patients with influenza presenting within 48 hours of symptom onset.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 12, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Improvement of Influenza Symptoms</measure>
    <time_frame>From Day 1 pretreatment up to Day 14</time_frame>
    <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9.</time_frame>
    <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus Titer at Each Time Point</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus Titer</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus RNA</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Symptoms Were Improved at Each Time Point</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment</time_frame>
    <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe).
Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity
Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of Symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of the Four Systemic Symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of the Three Respiratory Symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Normal Temperature at Each Time Point</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment</time_frame>
    <description>Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature at Each Time Point</measure>
    <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
    <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of Individual Symptoms</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours:
Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours.
Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Preinfluenza Health Status</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and condition]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection</measure>
    <time_frame>Day 2 to Day 22</time_frame>
    <description>The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Influenza-related Complications</measure>
    <time_frame>Day 1 to Day 22</time_frame>
    <description>Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2184</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir Marboxil</intervention_name>
    <description>Tablets taken orally</description>
    <arm_group_label>Baloxavir Marboxil</arm_group_label>
    <other_name>S-033188</other_name>
    <other_name>Xofluza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Baloxavir Marboxil</intervention_name>
    <description>Matching tablets taken orally</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Capsules taken orally</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <other_name>Tamiflu®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Oseltamivir</intervention_name>
    <description>Matching placebo capsules taken orally</description>
    <arm_group_label>Baloxavir Marboxil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients or their legal guardians who provide written informed consent to participate
             in the study on a voluntary basis. For adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements.

          2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent
             form.

          3. Patients with a diagnosis of influenza confirmed by all of the following:

               1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours
                  prior if antipyretics were taken

               2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a
                  negative RIDT may be enrolled if the patient reports contact with a known case of
                  influenza within the prior 7 days and all other inclusion criteria are met.

               3. At least 1 each of the following general and respiratory symptoms associated with
                  influenza is present with a severity of moderate or greater:

             i. General symptoms (headache, feverishness or chills, muscle or joint pain, or
             fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least 1 new general or respiratory symptom

          5. If a women of childbearing potential, agrees to use a highly effective method of
             contraception for 3 months after the first dose of study drug

          6. Patients will be considered at high risk* of influenza complications due to the
             presence of at least 1 of the following inclusion criteria:

               1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or
                  cystic fibrosis)

               2. Endocrine disorders (including diabetes mellitus)

               3. Residents of long-term care facilities (eg, nursing homes)

               4. Compromised immune system (including patients receiving corticosteroids not
                  exceeding 20 mg of prednisolone or equivalent, and patients being treated for
                  human immunodeficiency virus [HIV] infection with a CD4 count &gt; 350 cells/mm³
                  within the last 6 months)

               5. Neurological and neurodevelopmental disorders (including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, muscular dystrophy, or spinal cord injury)

               6. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms

               7. Adults aged ≥ 65 years

               8. American Indians and Alaskan Natives

               9. Blood disorders (such as sickle cell disease)

              10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial
                  disorders)

              11. Morbid obesity (body mass index ≥ 40 kg/m²)

              12. Women who are within 2 weeks postpartum and are not breastfeeding

        Exclusion Criteria:

          1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients with known allergy to oseltamivir (Tamiflu®).

          3. Patients unable to swallow tablets or capsules.

          4. Patients who have previously received baloxavir marboxil.

          5. Patients weighing ≤ 40 kg.

          6. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the
             predose examinations. The following female patients who have documentation of either a
             or b below do not need to undergo a pregnancy test at the predose examinations:

               1. Postmenopausal women (defined as cessation of regular menstrual periods for 2
                  years or more and confirmed by a follicle-stimulating hormone test)

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          8. Patients with concurrent infections at the predose examinations requiring systemic
             antimicrobial therapy.

          9. Patients with liver disease associated with hepatic impairment.

         10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).

         11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below
             350 cells/mm3 in the last 6 months.

         12. Patients with immunosuppression following organ or bone marrow transplants.

         13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic
             corticosteroids.

         14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir or amantadine within 30 days prior to the predose
             examinations.

         15. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         16. Patients with known creatinine clearance ≤ 60 mL/min.

         17. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <results_first_submitted>October 18, 2019</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2019</results_first_posted>
  <disposition_first_submitted>April 10, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 10, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 17, 2019</disposition_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamiflu®</keyword>
  <keyword>Influenza</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>Flu</keyword>
  <keyword>S-033188</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02949011/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02949011/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a multicenter study conducted at 551 sites, including 242 sites in the United States, 142 sites in Japan, 48 sites in APAC (including Australia, New Zealand, Philippines, and South Korea), 98 sites in Europe (Belgium, Germany, Hungary, Latvia, Poland, Romania, and Spain), and 21 sites in South Africa.</recruitment_details>
      <pre_assignment_details>Eligible patients were randomized in a 1:1:1 ratio to 1 of 3 treatment groups. Participants were stratified by baseline symptom score (≤ 14 or ≥ 15), preexisting and worsened symptom (Yes or No), region (Asia, North America/Europe, or Southern Hemisphere), and patient’s weight (&lt; 80 kg or ≥ 80 kg).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baloxavir Marboxil</title>
          <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
        </group>
        <group group_id="P3">
          <title>Oseltamivir</title>
          <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="730"/>
                <participants group_id="P2" count="729"/>
                <participants group_id="P3" count="725"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="728"/>
                <participants group_id="P2" count="728">Includes one participant who received baloxavir marboxil in error</participants>
                <participants group_id="P3" count="722">Includes one participant who received baloxavir marboxil in error</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat Infected Population</title>
              <participants_list>
                <participants group_id="P1" count="388"/>
                <participants group_id="P2" count="386"/>
                <participants group_id="P3" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="697"/>
                <participants group_id="P2" count="695"/>
                <participants group_id="P3" count="683"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Inclusion/Exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intention-to-treat Infected population includes all participants with a confirmed diagnosis of influenza virus infection who received study drug, and were enrolled at sites with Good Clinical Practice compliance. Confirmation of influenza virus infection was based on the results of reverse transcription polymerase chain reaction on Day 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Baloxavir Marboxil</title>
          <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
        </group>
        <group group_id="B3">
          <title>Oseltamivir</title>
          <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="388"/>
            <count group_id="B2" value="386"/>
            <count group_id="B3" value="389"/>
            <count group_id="B4" value="1163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="16.8"/>
                    <measurement group_id="B2" value="51.9" spread="16.7"/>
                    <measurement group_id="B3" value="51.1" spread="17.0"/>
                    <measurement group_id="B4" value="51.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥ 12 to ≤ 19 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 20 to ≤ 29 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 30 to ≤ 39 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 40 to ≤ 49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to ≤ 59 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 60 to ≤ 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 to ≤ 74 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="198"/>
                    <measurement group_id="B4" value="599"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="331"/>
                    <measurement group_id="B4" value="983"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="487"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 80 kg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="704"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 80 kg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to Treatment From Influenza Onset</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥ 0 to ≤ 12 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 12 to ≤ 24 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 24 to ≤ 36 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 36 to ≤ 48 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Virus Subtype Based on RT-PCR Assay</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>A/H1N1pdm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A/H3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="557"/>
                  </measurement_list>
                </category>
                <category>
                  <title>B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed infection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Virus Titer</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.</description>
          <population>Participants with available virus titer data</population>
          <units>log₁₀[TCID₅₀/mL]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="378"/>
                    <count group_id="B2" value="377"/>
                    <count group_id="B3" value="380"/>
                    <count group_id="B4" value="1135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.96" spread="2.28"/>
                    <measurement group_id="B2" value="5.27" spread="2.39"/>
                    <measurement group_id="B3" value="5.25" spread="2.27"/>
                    <measurement group_id="B4" value="5.16" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Virus Ribonucleic Acid (RNA) Load</title>
          <description>Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR) from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible.</description>
          <population>Participants with available influenza virus RNA data</population>
          <units>log₁₀ virus particles/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="385"/>
                    <count group_id="B2" value="378"/>
                    <count group_id="B3" value="387"/>
                    <count group_id="B4" value="1150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.72" spread="1.43"/>
                    <measurement group_id="B2" value="6.87" spread="1.54"/>
                    <measurement group_id="B3" value="6.81" spread="1.37"/>
                    <measurement group_id="B4" value="6.80" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="462"/>
                  </measurement_list>
                </category>
                <category>
                  <title>North America/Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="220"/>
                    <measurement group_id="B4" value="648"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Southern Hemisphere</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Composite Symptom Score</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ 14</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="577"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 15</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preexisting Symptom Status</title>
          <description>Preexisting symptoms include cough, fatigue, or muscle/joint pain that existed prior to developing influenza.
Participants were asked at baseline if they had any of these preexisting symptoms in the past 30 days, and if they were worsened by the onset of influenza.
Participants with at least 1 of the above 3 symptoms prior to onset of influenza that worsened with the onset of influenza were categorized as “Yes”, and all other participants (preexisting symptoms but not worsened or no preexisting symptoms) were categorized as “No”.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="388"/>
                    <count group_id="B2" value="386"/>
                    <count group_id="B3" value="389"/>
                    <count group_id="B4" value="1163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="320"/>
                    <measurement group_id="B4" value="947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Improvement of Influenza Symptoms</title>
        <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.</description>
        <time_frame>From Day 1 pretreatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population with available time to improvement of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of Influenza Symptoms</title>
          <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.</description>
          <population>Participants in the intention-to-treat infected population with available time to improvement of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" lower_limit="67.2" upper_limit="85.1"/>
                    <measurement group_id="O2" value="102.3" lower_limit="92.7" upper_limit="113.1"/>
                    <measurement group_id="O3" value="81.0" lower_limit="69.4" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis of the primary endpoint was a comparison between the baloxavir marboxil and placebo groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted p-value, two-sided significance level of 0.05</p_value_desc>
            <method>Stratified generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-29.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.8</ci_lower_limit>
            <ci_upper_limit>-14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The comparison between the baloxavir marboxil and the oseltamivir groups was conducted as a secondary analysis only if a statistically significant difference was observed in the primary analysis in order to maintain control of overall type I error.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8347</p_value>
            <p_value_desc>Adjusted p-value, two-sided significance level of 0.05</p_value_desc>
            <method>Stratified generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.7</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis using the stratified log rank test was performed as a sensitivity analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis using the stratified log rank test was performed as a sensitivity analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8449</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infected population with a positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.</description>
          <population>Participants in the intention-to-treat infected population with a positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="53.2" upper_limit="63.9"/>
                    <measurement group_id="O2" value="86.9" lower_limit="82.9" upper_limit="90.3"/>
                    <measurement group_id="O3" value="86.9" lower_limit="82.9" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="337"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="26.7" upper_limit="36.9"/>
                    <measurement group_id="O2" value="72.7" lower_limit="67.6" upper_limit="77.4"/>
                    <measurement group_id="O3" value="60.0" lower_limit="54.6" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="12.2" upper_limit="26.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="40.8" upper_limit="59.2"/>
                    <measurement group_id="O3" value="33.1" lower_limit="24.9" upper_limit="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="12.1" upper_limit="20.4"/>
                    <measurement group_id="O2" value="30.7" lower_limit="25.7" upper_limit="36.1"/>
                    <measurement group_id="O3" value="20.4" lower_limit="16.2" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.4" upper_limit="9.9"/>
                    <measurement group_id="O2" value="16.0" lower_limit="9.6" upper_limit="24.4"/>
                    <measurement group_id="O3" value="11.4" lower_limit="6.0" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.3" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.1" upper_limit="8.3"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0044</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1146</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.441</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0929</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0907</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point</title>
        <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9.</time_frame>
        <population>Participants in the intention-to-treat infected population with positive influenza virus RNA determined by RT-PCR on Day 1 and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point</title>
          <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.</description>
          <population>Participants in the intention-to-treat infected population with positive influenza virus RNA determined by RT-PCR on Day 1 and with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="375"/>
                    <count group_id="O3" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="93.4" upper_limit="97.7"/>
                    <measurement group_id="O2" value="96.3" lower_limit="93.8" upper_limit="97.9"/>
                    <measurement group_id="O3" value="96.0" lower_limit="93.5" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="372"/>
                    <count group_id="O3" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="89.4" upper_limit="95.0"/>
                    <measurement group_id="O2" value="95.4" lower_limit="92.8" upper_limit="97.3"/>
                    <measurement group_id="O3" value="95.1" lower_limit="92.4" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="79.9" upper_limit="91.5"/>
                    <measurement group_id="O2" value="91.0" lower_limit="85.1" upper_limit="95.1"/>
                    <measurement group_id="O3" value="86.4" lower_limit="79.6" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="361"/>
                    <count group_id="O3" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="80.8" upper_limit="88.4"/>
                    <measurement group_id="O2" value="88.6" lower_limit="84.9" upper_limit="91.7"/>
                    <measurement group_id="O3" value="86.1" lower_limit="82.2" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="63.2" upper_limit="79.3"/>
                    <measurement group_id="O2" value="78.0" lower_limit="69.7" upper_limit="85.0"/>
                    <measurement group_id="O3" value="71.8" lower_limit="62.7" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="49.3" upper_limit="59.8"/>
                    <measurement group_id="O2" value="64.9" lower_limit="59.7" upper_limit="69.8"/>
                    <measurement group_id="O3" value="57.7" lower_limit="52.3" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7383</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9619</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0576</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1237</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3071</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9603</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0784</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5547</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3087</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9106</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3068</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus Titer at Each Time Point</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infected population with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus Titer at Each Time Point</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
          <population>Participants in the intention-to-treat infected population with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>log₁₀[TCID₅₀/mL]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="343"/>
                    <count group_id="O3" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="2.21"/>
                    <measurement group_id="O2" value="-1.25" spread="2.27"/>
                    <measurement group_id="O3" value="-1.76" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="336"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="2.22"/>
                    <measurement group_id="O2" value="-2.99" spread="2.55"/>
                    <measurement group_id="O3" value="-3.26" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.99" spread="2.00"/>
                    <measurement group_id="O2" value="-3.79" spread="2.75"/>
                    <measurement group_id="O3" value="-3.75" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.32" spread="2.16"/>
                    <measurement group_id="O2" value="-4.38" spread="2.31"/>
                    <measurement group_id="O3" value="-4.41" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" spread="2.05"/>
                    <measurement group_id="O2" value="-4.68" spread="2.22"/>
                    <measurement group_id="O3" value="-4.39" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="320"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.53" spread="2.11"/>
                    <measurement group_id="O2" value="-4.91" spread="2.08"/>
                    <measurement group_id="O3" value="-4.78" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0024</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9127</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ven Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5361</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5739</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5466</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0543</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4677</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1281</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point</title>
        <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infected population with positive RT-PCR on Day 1 and with available virus RNA data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point</title>
          <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
          <population>Participants in the intention-to-treat infected population with positive RT-PCR on Day 1 and with available virus RNA data at each time point.</population>
          <units>log₁₀ virus particles/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.20"/>
                    <measurement group_id="O2" value="-0.62" spread="1.34"/>
                    <measurement group_id="O3" value="-0.76" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.45"/>
                    <measurement group_id="O2" value="-1.57" spread="1.66"/>
                    <measurement group_id="O3" value="-1.77" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="1.42"/>
                    <measurement group_id="O2" value="-2.09" spread="1.84"/>
                    <measurement group_id="O3" value="-2.34" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" spread="1.58"/>
                    <measurement group_id="O2" value="-2.77" spread="1.67"/>
                    <measurement group_id="O3" value="-3.04" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="1.48"/>
                    <measurement group_id="O2" value="-3.19" spread="1.77"/>
                    <measurement group_id="O3" value="-3.41" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="349"/>
                    <count group_id="O3" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="1.51"/>
                    <measurement group_id="O2" value="-3.78" spread="1.65"/>
                    <measurement group_id="O3" value="-3.99" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0265</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0247</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5298</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9554</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9075</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7624</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6156</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer</title>
        <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infected population with a positive virus titer on Day 1 and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer</title>
          <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infected population with a positive virus titer on Day 1 and available sample on Day 9.</population>
          <units>log₁₀[TCID₅₀/mL]*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-727.7" spread="367.2"/>
                    <measurement group_id="O2" value="-660.2" spread="372.3"/>
                    <measurement group_id="O3" value="-695.5" spread="360.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0340</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2766</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA</title>
        <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infected population with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA</title>
          <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infected population with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
          <units>log₁₀ virus particles/mL*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-490.9" spread="249.3"/>
                    <measurement group_id="O2" value="-434.9" spread="269.3"/>
                    <measurement group_id="O3" value="-482.2" spread="233.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7330</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus Titer</title>
        <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infected population with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus Titer</title>
          <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infected population with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="352"/>
                <count group_id="O3" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="NA" upper_limit="NA">Could not be estimated because lower limit of 95% CI of KM survival function just before the median survival time was higher than 50% and an upper limit of 95% CI of KM survival function just after the median survival time was lower than 50%.</measurement>
                    <measurement group_id="O2" value="96.0" lower_limit="NA" upper_limit="NA">Could not be estimated because lower limit of 95% CI of KM survival function just before the median survival time was higher than 50% and an upper limit of 95% CI of KM survival function just after the median survival time was lower than 50%.</measurement>
                    <measurement group_id="O3" value="96.0" lower_limit="72.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-48.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.0</ci_lower_limit>
            <ci_upper_limit>-48.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-48.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.0</ci_lower_limit>
            <ci_upper_limit>-24.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus RNA</title>
        <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infected population with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RT-PCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus RNA</title>
          <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infected population with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RT-PCR.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.0" lower_limit="192.0" upper_limit="240.0"/>
                    <measurement group_id="O2" value="240.0" lower_limit="216.0" upper_limit="312.0"/>
                    <measurement group_id="O3" value="216.0" lower_limit="216.0" upper_limit="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-24.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-96.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2370</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.0</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Whose Symptoms Were Improved at Each Time Point</title>
        <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe).
Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity
Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infected population with available symptoms data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Whose Symptoms Were Improved at Each Time Point</title>
          <description>Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe).
Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity
Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).</description>
          <population>Participants in the intention-to-treat infected population with available symptoms data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.1" upper_limit="13.0"/>
                    <measurement group_id="O2" value="8.6" lower_limit="5.7" upper_limit="12.3"/>
                    <measurement group_id="O3" value="8.1" lower_limit="5.3" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="365"/>
                    <count group_id="O3" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="14.9" upper_limit="23.2"/>
                    <measurement group_id="O2" value="14.2" lower_limit="10.8" upper_limit="18.3"/>
                    <measurement group_id="O3" value="19.6" lower_limit="15.7" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="304"/>
                    <count group_id="O3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" lower_limit="28.6" upper_limit="39.5"/>
                    <measurement group_id="O2" value="21.1" lower_limit="16.6" upper_limit="26.1"/>
                    <measurement group_id="O3" value="31.0" lower_limit="25.8" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="368"/>
                    <count group_id="O3" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="33.0" upper_limit="43.2"/>
                    <measurement group_id="O2" value="28.8" lower_limit="24.2" upper_limit="33.7"/>
                    <measurement group_id="O3" value="39.9" lower_limit="34.9" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="359"/>
                    <count group_id="O3" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="50.7" upper_limit="61.2"/>
                    <measurement group_id="O2" value="41.8" lower_limit="36.6" upper_limit="47.1"/>
                    <measurement group_id="O3" value="56.0" lower_limit="50.6" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                    <count group_id="O2" value="341"/>
                    <count group_id="O3" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" lower_limit="60.7" upper_limit="70.9"/>
                    <measurement group_id="O2" value="53.4" lower_limit="47.9" upper_limit="58.8"/>
                    <measurement group_id="O3" value="61.1" lower_limit="55.8" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="342"/>
                    <count group_id="O3" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="67.4" upper_limit="76.9"/>
                    <measurement group_id="O2" value="64.6" lower_limit="59.3" upper_limit="69.7"/>
                    <measurement group_id="O3" value="72.4" lower_limit="67.2" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="342"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" lower_limit="73.4" upper_limit="82.3"/>
                    <measurement group_id="O2" value="69.6" lower_limit="64.4" upper_limit="74.4"/>
                    <measurement group_id="O3" value="77.6" lower_limit="72.7" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="326"/>
                    <count group_id="O3" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="75.5" upper_limit="84.2"/>
                    <measurement group_id="O2" value="72.7" lower_limit="67.5" upper_limit="77.5"/>
                    <measurement group_id="O3" value="79.6" lower_limit="74.8" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="341"/>
                    <count group_id="O2" value="337"/>
                    <count group_id="O3" value="327"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="79.2" upper_limit="87.3"/>
                    <measurement group_id="O2" value="78.0" lower_limit="73.2" upper_limit="82.3"/>
                    <measurement group_id="O3" value="85.6" lower_limit="81.3" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8" lower_limit="80.1" upper_limit="90.3"/>
                    <measurement group_id="O2" value="78.7" lower_limit="71.9" upper_limit="84.6"/>
                    <measurement group_id="O3" value="88.2" lower_limit="82.5" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7698</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5777</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1112</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6483</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5625</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6234</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9547</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1860</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0274</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9635</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0081</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7425</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0209</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7448</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0644</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4931</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0708</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4024</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of Symptoms</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population with available time to alleviation of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Symptoms</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infected population with available time to alleviation of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="68.4" upper_limit="88.3"/>
                    <measurement group_id="O2" value="102.8" lower_limit="93.2" upper_limit="113.4"/>
                    <measurement group_id="O3" value="85.6" lower_limit="71.5" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-25.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9127</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-8.6</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement of the Four Systemic Symptoms</title>
        <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population with available time to improvement of the 4 systemic symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of the Four Systemic Symptoms</title>
          <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.</description>
          <population>Participants in the intention-to-treat infected population with available time to improvement of the 4 systemic symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="45.0" upper_limit="55.4"/>
                    <measurement group_id="O2" value="66.8" lower_limit="60.1" upper_limit="70.0"/>
                    <measurement group_id="O3" value="49.4" lower_limit="44.2" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-15.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8498</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>2.3</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement of the Three Respiratory Symptoms</title>
        <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population with available time to improvement of the 3 respiratory symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of the Three Respiratory Symptoms</title>
          <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infected population with available time to improvement of the 3 respiratory symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="55.9" upper_limit="68.2"/>
                    <measurement group_id="O2" value="87.8" lower_limit="76.3" upper_limit="98.9"/>
                    <measurement group_id="O3" value="62.1" lower_limit="54.0" upper_limit="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-24.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9237</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>1.5</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever</title>
        <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever</title>
          <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infected population whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" lower_limit="28.2" upper_limit="35.4"/>
                    <measurement group_id="O2" value="50.7" lower_limit="44.6" upper_limit="58.8"/>
                    <measurement group_id="O3" value="34.3" lower_limit="30.0" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-19.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.8</ci_lower_limit>
            <ci_upper_limit>-12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2425</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Normal Temperature at Each Time Point</title>
        <description>Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infected population whose body temperature at baseline was more than 37°C and with available body temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Normal Temperature at Each Time Point</title>
          <description>Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.</description>
          <population>Participants in the intention-to-treat infected population whose body temperature at baseline was more than 37°C and with available body temperature data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" lower_limit="24.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="24.6" lower_limit="20.1" upper_limit="29.5"/>
                    <measurement group_id="O3" value="25.9" lower_limit="21.3" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" lower_limit="45.8" upper_limit="56.4"/>
                    <measurement group_id="O2" value="43.2" lower_limit="38.1" upper_limit="48.5"/>
                    <measurement group_id="O3" value="54.3" lower_limit="49.1" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="345"/>
                    <count group_id="O2" value="352"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="62.9" upper_limit="73.0"/>
                    <measurement group_id="O2" value="47.4" lower_limit="42.1" upper_limit="52.8"/>
                    <measurement group_id="O3" value="64.1" lower_limit="58.8" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="371"/>
                    <count group_id="O3" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="72.8" upper_limit="81.6"/>
                    <measurement group_id="O2" value="59.3" lower_limit="54.1" upper_limit="64.3"/>
                    <measurement group_id="O3" value="76.4" lower_limit="71.7" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="336"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="79.6" upper_limit="87.7"/>
                    <measurement group_id="O2" value="71.7" lower_limit="66.6" upper_limit="76.5"/>
                    <measurement group_id="O3" value="82.6" lower_limit="78.0" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="331"/>
                    <count group_id="O3" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="83.5" upper_limit="90.9"/>
                    <measurement group_id="O2" value="79.8" lower_limit="75.0" upper_limit="84.0"/>
                    <measurement group_id="O3" value="85.8" lower_limit="81.5" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="82.0" upper_limit="89.8"/>
                    <measurement group_id="O2" value="86.6" lower_limit="82.4" upper_limit="90.1"/>
                    <measurement group_id="O3" value="88.4" lower_limit="84.3" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="86.1" upper_limit="93.0"/>
                    <measurement group_id="O2" value="86.1" lower_limit="81.9" upper_limit="89.7"/>
                    <measurement group_id="O3" value="87.4" lower_limit="83.1" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" lower_limit="83.8" upper_limit="91.2"/>
                    <measurement group_id="O2" value="88.1" lower_limit="84.0" upper_limit="91.5"/>
                    <measurement group_id="O3" value="87.7" lower_limit="83.4" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="85.0" upper_limit="92.2"/>
                    <measurement group_id="O2" value="87.5" lower_limit="83.3" upper_limit="91.0"/>
                    <measurement group_id="O3" value="90.5" lower_limit="86.5" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="85.1" upper_limit="92.3"/>
                    <measurement group_id="O2" value="89.9" lower_limit="85.9" upper_limit="93.1"/>
                    <measurement group_id="O3" value="89.6" lower_limit="85.7" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1713</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2249</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0387</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3915</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2617</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8808</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5923</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6746</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8167</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3773</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1041</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3328</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7867</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8640</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6465</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4265</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6568</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6102</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature at Each Time Point</title>
        <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
        <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infected population with available temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature at Each Time Point</title>
          <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
          <population>Participants in the intention-to-treat infected population with available temperature data at each time point.</population>
          <units>°C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.39" spread="0.07"/>
                    <measurement group_id="O2" value="37.53" spread="0.07"/>
                    <measurement group_id="O3" value="37.43" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.84" spread="0.06"/>
                    <measurement group_id="O2" value="37.02" spread="0.06"/>
                    <measurement group_id="O3" value="36.80" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="346"/>
                    <count group_id="O2" value="352"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.58" spread="0.06"/>
                    <measurement group_id="O2" value="36.94" spread="0.06"/>
                    <measurement group_id="O3" value="36.62" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="371"/>
                    <count group_id="O3" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.44" spread="0.06"/>
                    <measurement group_id="O2" value="36.77" spread="0.06"/>
                    <measurement group_id="O3" value="36.50" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="336"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.30" spread="0.05"/>
                    <measurement group_id="O2" value="36.46" spread="0.05"/>
                    <measurement group_id="O3" value="36.29" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="331"/>
                    <count group_id="O3" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.26" spread="0.05"/>
                    <measurement group_id="O2" value="36.35" spread="0.05"/>
                    <measurement group_id="O3" value="36.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.26" spread="0.05"/>
                    <measurement group_id="O2" value="36.27" spread="0.05"/>
                    <measurement group_id="O3" value="36.21" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0408</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5324</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4874</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5414</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3185</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8299</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0878</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7498</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8030</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3577</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement of Individual Symptoms</title>
        <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours:
Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours.
Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population; the analysis of each individual symptom includes participants with new or preexisting and worsened symptom scores of moderate (2) or severe (3) at baseline, and with available time to improvement of symptom data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of Individual Symptoms</title>
          <description>Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours:
Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours.
Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.</description>
          <population>Participants in the intention-to-treat infected population; the analysis of each individual symptom includes participants with new or preexisting and worsened symptom scores of moderate (2) or severe (3) at baseline, and with available time to improvement of symptom data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="42.8" upper_limit="52.7"/>
                    <measurement group_id="O2" value="70.4" lower_limit="56.5" upper_limit="79.5"/>
                    <measurement group_id="O3" value="47.5" lower_limit="43.0" upper_limit="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="32.4" upper_limit="46.1"/>
                    <measurement group_id="O2" value="46.5" lower_limit="39.0" upper_limit="53.5"/>
                    <measurement group_id="O3" value="39.3" lower_limit="30.1" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" lower_limit="29.1" upper_limit="40.5"/>
                    <measurement group_id="O2" value="43.9" lower_limit="33.6" upper_limit="46.2"/>
                    <measurement group_id="O3" value="31.3" lower_limit="28.6" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="37.4" upper_limit="54.3"/>
                    <measurement group_id="O2" value="57.7" lower_limit="48.7" upper_limit="67.8"/>
                    <measurement group_id="O3" value="44.0" lower_limit="36.4" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feverishness or Chills</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="24.2" upper_limit="31.8"/>
                    <measurement group_id="O2" value="31.9" lower_limit="28.6" upper_limit="41.2"/>
                    <measurement group_id="O3" value="29.1" lower_limit="25.2" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle or Joint Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" lower_limit="31.5" upper_limit="41.6"/>
                    <measurement group_id="O2" value="44.9" lower_limit="42.2" upper_limit="52.0"/>
                    <measurement group_id="O3" value="33.2" lower_limit="30.2" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="35.2" upper_limit="46.1"/>
                    <measurement group_id="O2" value="48.8" lower_limit="42.7" upper_limit="55.4"/>
                    <measurement group_id="O3" value="43.2" lower_limit="39.3" upper_limit="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cough</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-23.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cough</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4074</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-0.2</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sore Throat</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2496</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-6.3</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sore Throat</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2963</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>0.9</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0390</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-10.6</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7877</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>2.0</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nasal Congestion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-12.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal Congestion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8119</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>1.5</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Feverishness or Chills</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0070</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-3.6</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Feverishness or Chills</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9191</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-0.7</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Muscle or Joint Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0232</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-7.7</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Muscle or Joint Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5436</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>4.0</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0207</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-7.5</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3710</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-1.9</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Preinfluenza Health Status</title>
        <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and condition]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
        <time_frame>Baseline to Day 14</time_frame>
        <population>Participants in the intention-to-treat infected population whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Preinfluenza Health Status</title>
          <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and condition]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infected population whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.4" lower_limit="104.6" upper_limit="153.4"/>
                    <measurement group_id="O2" value="149.8" lower_limit="124.7" upper_limit="175.7"/>
                    <measurement group_id="O3" value="126.9" lower_limit="104.9" upper_limit="152.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4634</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-23.4</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6386</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Peto-Prentice’s generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.</method_desc>
            <param_type>Median Difference</param_type>
            <param_value>-0.6</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection</title>
        <description>The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).</description>
        <time_frame>Day 2 to Day 22</time_frame>
        <population>Intention-to-treat infected population</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection</title>
          <description>The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).</description>
          <population>Intention-to-treat infected population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.8" upper_limit="5.7"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.1" upper_limit="10.6"/>
                    <measurement group_id="O3" value="3.9" lower_limit="2.2" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0112</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8478</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Influenza-related Complications</title>
        <description>Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.</description>
        <time_frame>Day 1 to Day 22</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza-related Complications</title>
          <description>Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.</description>
          <population>Intention-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.4" upper_limit="5.0"/>
                    <measurement group_id="O2" value="10.4" lower_limit="7.5" upper_limit="13.8"/>
                    <measurement group_id="O3" value="4.6" lower_limit="2.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.4" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.3" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.4"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.9" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.2" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="6.0" lower_limit="3.8" upper_limit="8.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.2" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Any Complications</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Any Complications</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2558</p_value>
            <p_value_desc>The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <time_frame>From first dose of study drug to Day 22</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir Marboxil</title>
            <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
                <count group_id="O2" value="727"/>
                <count group_id="O3" value="721"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1"/>
                    <measurement group_id="O2" value="29.7"/>
                    <measurement group_id="O3" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events (TRAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAEs leading to withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality data are reported from Day 1 though Day 22. Adverse events are reported from the first dose of study drug through Day 22 (i.e. treatment-emergent adverse events).</time_frame>
      <desc>One participant randomized to placebo and one participant randomized to oseltamivir received baloxavir marboxil in error, and are counted in the baloxavir marboxil, treatment group for safety analyses.
One participant died after a myocardial infarction that occurred prior to receiving any study drug; although this death is included in the all-cause mortality table this death was not considered treatment-emergent.</desc>
      <group_list>
        <group group_id="E1">
          <title>Baloxavir Marboxil</title>
          <description>Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of &lt; 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.</description>
        </group>
        <group group_id="E3">
          <title>Oseltamivir</title>
          <description>Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="721"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="730"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="727"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="721"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

